Back to News
Market Impact: 0.15

Detailed Fundamental Analysis

SPYVNDAQ
Company FundamentalsAnalyst InsightsInvestor Sentiment & PositioningHealthcare & Biotech
Detailed Fundamental Analysis

Validea's fundamental report on the SPDR Portfolio S&P 500 Value ETF (SPYV) characterizes it as a Large-Cap Low Volatility ETF, with its highest factor exposure in low volatility (84/99), moderate exposure to value (64/99) and quality (58/99), and low momentum (28/99). The ETF's portfolio is primarily concentrated in the Financial sector and the Biotechnology & Drugs industry.

Analysis

According to Validea's fundamental report, the SPDR Portfolio S&P 500 Value ETF (SPYV) exhibits a distinct factor profile, primarily characterized by its high exposure to low volatility, scoring 84 out of 99. While its name emphasizes value, its exposure to this factor is moderate, with a score of 64, similar to its quality score of 58. A key characteristic is the ETF's very low momentum score of 28, suggesting it does not hold stocks that have recently exhibited strong price performance. The portfolio's composition is heavily weighted towards the Financial sector, and its single largest industry concentration is in Biotechnology & Drugs. This profile positions SPYV as a large-cap ETF that blends value and quality attributes with a primary objective of reducing volatility, rather than pursuing pure value or momentum strategies.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.00

Ticker Sentiment

NDAQ0.00
SPYV0.00

Key Decisions for Investors

  • Investors seeking to de-risk portfolios or add a defensive tilt may find SPYV suitable, given its high low-volatility score of 84 and moderate quality score of 58.
  • Momentum-focused investors should be aware that this ETF's low momentum score of 28 indicates it will likely underperform in strongly trending upward markets.
  • Given the significant concentration in the Financials and Biotechnology & Drugs industries, investors should assess their existing sector exposures to avoid unintended overweighting.
  • While named a 'Value' ETF, its moderate value score of 64 suggests it is not a deep-value fund, but rather a vehicle that balances value characteristics with a low-volatility mandate.